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1. **INTRODUCTIO**N {#mgg3850-sec-0005}
===================

Lynch Syndrome (LS) is an autosomal dominantly inherited predisposition to colorectal cancer (CRC) and other epithelial malignancies and accounts for approximately 2%--3% of all CRC patients diagnosed annually (de la Chapelle, [2004](#mgg3850-bib-0007){ref-type="ref"}; Hampel et al., [2005](#mgg3850-bib-0013){ref-type="ref"}). LS, also known as hereditary nonpolyposis colorectal cancer (HNPCC), is defined by the presence of germline mutations in one of four genes involved in DNA mismatch repair (MMR); *MLH1* (OMIM: 120436), *MSH2* (OMIM: 609309), *MSH6* (OMIM: 600678), and *PMS2* (OMIM: 600259) (Lynch & de la Chapelle, [1999](#mgg3850-bib-0029){ref-type="ref"}). Deletions in *EPCAM* are also implicated in LS that are associated with epigenetic silencing of *MSH2* (Kuiper et al., [2011](#mgg3850-bib-0022){ref-type="ref"}). It is important to identify LS mutation carriers, in order to offer them regular surveillance programs like colonoscopy to improve early detection of cancer.

LS tumor spectrum is quite wide, involving in most cases CRC and, for women, a high risk of endometrial cancer (Lek et al., [2016](#mgg3850-bib-0023){ref-type="ref"}). In addition, MMR mutations in LS causes an increased risk of ovarian, gastric, urologic tract, kidney, ureter, small bowel, and hepatobiliary tract tumors (Samadder et al., [2017](#mgg3850-bib-0036){ref-type="ref"}; Watson & Riley, [2005](#mgg3850-bib-0047){ref-type="ref"}).

LS is an entity that has been diagnosed using the Amsterdam criteria (AC) and Bethesda guidelines (BG), or variants of it (the AC II or revised BG) using the patient\'s pedigree and family history of cancer (Rodriguez‐Bigas et al., [1997](#mgg3850-bib-0035){ref-type="ref"}; Umar et al., [2004](#mgg3850-bib-0039){ref-type="ref"}; Vasen, Mecklin, Khan, & Lynch, [1991](#mgg3850-bib-0041){ref-type="ref"}; Vasen, Watson, Mecklin, & Lynch, [1999](#mgg3850-bib-0042){ref-type="ref"}). Genetic screening by Sanger sequencing to identify causative variants in MMR genes has been the gold standard to diagnose patients at risk of LS. Individuals fulfilling the AC II or revised BG without a molecular diagnosis are now termed Lynch‐like syndrome (LLS) families (Carethers, [2014](#mgg3850-bib-0005){ref-type="ref"}; Giardiello et al., [2014](#mgg3850-bib-0011){ref-type="ref"}).

Families that fulfill the AC, where probands have tumors displaying microsatellite instability (MSI) or a loss of MMR genes expression (as judged by immunohistochemistry), are offered screening for pathogenic variants in MMR genes (usually by DNA sequencing) to identify a causative genetic variant. Using this approach, approximately 50% of LS patients remain without a molecular diagnosis after screening the common MMR genes (Bonis et al., [2007](#mgg3850-bib-0003){ref-type="ref"}; Lindor et al., [2005](#mgg3850-bib-0026){ref-type="ref"}; Steinke et al., [2014](#mgg3850-bib-0037){ref-type="ref"}). Early detection and management provide the best likelihood of survival, thus identifying high‐risk individuals who could benefit from early detection is a priority. The 50% of patients where pathogenic variants cannot be detected are commonly termed LLS families or familial colorectal cancer type X (FCCTX) as disease segregation is suggestive of an inherited disease but in the absence of any identifiable causative variant. This group appears to have a later age of disease onset compared to LS, suggesting that these families have lower levels of disease penetrance (Lipkin & Afrasiabi, [2007](#mgg3850-bib-0027){ref-type="ref"}). While the definitions of LLS and FCCTX mostly overlap, LLS is defined by patients with MSI‐High tumors but no loss of MMR immunohistochemistry staining (for the four main MMR genes) (Carethers, [2014](#mgg3850-bib-0005){ref-type="ref"}). On the other hand, FCCTX describes patients fulfilling the AC I but no causative pathogenic variants has been found, and are mostly microsatellite‐stable (MSS) (Lipkin & Afrasiabi, [2007](#mgg3850-bib-0027){ref-type="ref"}).

DNA MMR involves the coordinated response of at least 22 proteins (KEGG pathways (Kanehisa, Furumichi, Tanabe, Sato, & Morishima, [2017](#mgg3850-bib-0020){ref-type="ref"}), Figure [1](#mgg3850-fig-0001){ref-type="fig"}) that are involved in mismatch recognition, protein recruitment to the lesion, removal of the mismatch and replacement of the incorrect base with the correct one (Fishel, [2015](#mgg3850-bib-0010){ref-type="ref"}). Thus, the possibility exists that other defects in the DNA MMR pathway may be associated with cancer risk, which manifests as an entity similar to LS. Evidence to support this comes from studies that have examined *MLH3* where it has been proposed to be a candidate gene implicated in LS (Liu et al., [2003](#mgg3850-bib-0028){ref-type="ref"}). This is supported by evidence that demonstrates *MSH3* variants appear to confer a low risk of disease (associated with various phenotypes (Carethers, Koi, & Tseng‐Rogenski, [2015](#mgg3850-bib-0006){ref-type="ref"}) including a phenotype of polyposis (Adam et al., [2016](#mgg3850-bib-0001){ref-type="ref"})) and have a synergistic effect when accompanied by *MSH2* variants (Duraturo et al., [2011](#mgg3850-bib-0009){ref-type="ref"}). Previously, *POLD1* variants have shown to be associated with an increased risk of CRC that results in a phenotypic disease spectrum, which includes phenotypes, observed in both LS and a polyposis (Buchanan et al., [2017](#mgg3850-bib-0004){ref-type="ref"}).

To assess the involvement of other MMR genes in LS, we investigated the presence of potentially pathogenic variants in 22 MMR genes (*MSH3*, *PMS1*, *MLH3* (OMIM: 604395), *EXO1* (OMIM: 606063), *POLD1* (OMIM: 174761), *POLD3*, *RFC1* (OMIM: 102579), *RFC2*, *RFC3*, *RFC4*, *RFC5*, *PCNA*, *LIG1*, *RPA1* (OMIM: 179835), *RPA2*, *RPA3*, *POLD2*, *POLD4*, *MLH1*, *MSH2*, *MSH6*, and *PMS2*), using next‐generation sequencing (NGS) in patients with a clinical diagnosis of LS. All of whom fulfilled the ACII or the revised BG but lacked a causative variant for the standard MMR gene(s) after genetic testing.

2. METHODS {#mgg3850-sec-0006}
==========

2.1. Ethics approval {#mgg3850-sec-0007}
--------------------

Ethics approval was obtained from the Hunter New England Human Research Ethics Committee (04/03/10/3.11) and the University of Newcastle Human Research Ethics Committee (H‐2008--0337).

2.2. Samples {#mgg3850-sec-0008}
------------

This study used DNA obtained from 82 Norwegian and 192 Australian LLS patients (*n* = 274, see Table [1](#mgg3850-tbl-0001){ref-type="table"}) previously described (Hansen et al., [2017](#mgg3850-bib-0014){ref-type="ref"}). In brief, all patients fulfilled the AC II criteria or revised BG and had no pathogenic variant detected during routine genetic screening for the MMR gene(s) tested (*MLH1*, *MSH2*, *MSH6*, and/or *PMS2*). All patients were previously screened for one or more MMR genes as per their practician recommendations.

###### 

Cohort characteristics and screening results for the 274 samples included in the current study

                                                                            Total Cohort (*N* = 274)
  ------------------------------------------------------------------------- --------------------------
  Nationality                                                                
  Norwegian                                                                 82
  Australian                                                                192
  Female                                                                    183
  Male                                                                      91
  Median age at first cancer[a](#mgg3850-note-0001){ref-type="fn"}          51.5 \[21--86\]
  Cancer history[b](#mgg3850-note-0002){ref-type="fn"}                       
  CRC                                                                       229
  Other cancers                                                             28
  Only adenomas                                                             14
  Multiple primary cancers                                                  64
  Amsterdam Criteria II                                                      
  Positive                                                                  262
  Negative[c](#mgg3850-note-0003){ref-type="fn"}                            12
  Microsatellite instability status[d](#mgg3850-note-0004){ref-type="fn"}    
  MSS                                                                       38
  MSI‐L                                                                     6
  MSI‐H                                                                     27
  IHC[e](#mgg3850-note-0005){ref-type="fn"}                                  
  Loss of MMR protein staining                                              83
  Normal staining                                                           56

Data missing for six patients.

Data missing for three patients.

Revised Bethesda Guidelines (BG) positive.

Only available for the Norwegian patients. Data missing for 203 patients.

Data available for 68 Norwegian and 71 Australian samples. Data missing for 135 patients.

John Wiley & Sons, Ltd

The sample cohort consisted of unrelated (Australian) and unrelated/related (Norwegian) individuals; eight families with two to three individuals per family were present in the Norwegian cohort (Hansen et al., [2017](#mgg3850-bib-0014){ref-type="ref"}).

DNA samples from all patients were sequenced as part of the health‐care system and all patients have given written informed consent for their samples to be used for research. Ethics approval was obtained from relevant committees.

2.3. Gene panel sequencing {#mgg3850-sec-0009}
--------------------------

Sequencing data were generated (See Figure [S1](#mgg3850-sup-0001){ref-type="supplementary-material"}) from a 124 multigene panel study described in (Hansen et al., [2017](#mgg3850-bib-0014){ref-type="ref"}), which contained 22 MMR genes (*MLH1*, *MSH2*, *MSH6*, *PMS2*, *MSH3*, *PMS1*, *MLH3*, *EXO1*, *POLD1*, *POLD3*, *RFC1*, *RFC2*, *RFC3*, *RFC4*, *FRC5*, *PCNA*, *LIG1*, *RPA1*, *RPA2*, *RPA3*, *POLD2*, *and POLD4*).

A custom Haloplex design (Agilent Technologies, Santa Clara, CA) was used for library preparation. Description of both the Haloplex design and the sequencing protocols (HiSeq 2500 and NextSeq, Illumina) have been reported previously (Hansen et al., [2017](#mgg3850-bib-0014){ref-type="ref"}).

2.4. Data analysis {#mgg3850-sec-0010}
------------------

The previous (Hansen et al., [2017](#mgg3850-bib-0014){ref-type="ref"}) study analyzed only 10 MMR genes, (*MLH1*, *MSH2*, *MSH6*, *PMS2*, MSH3, *PMS*1, *MLH3*, *EXO1*, *POLD1*, and *POLD3*). In this current study, we included data from those genes as well as data from the remaining 12 MMR genes (*RFC1*, *RFC2*, *RFC3*, *RFC4*, *FRC5*, *PCNA*, *LIG1*, *RPA1*, *RPA2*, *RPA3*, *POLD2*, and *POLD4*) to create a complete MMR gene panel (See Figure [S1](#mgg3850-sup-0001){ref-type="supplementary-material"} for a full flowchart of the study\'s design).

Burrows‐Wheeler Aligner (BWA) (Li & Durbin, [2009](#mgg3850-bib-0024){ref-type="ref"}) was utilized to align the paired end reads to the human genome (hg19, UCSC assembly, February 2009). BAM files were converted with SAMtools (Li et al., [2009](#mgg3850-bib-0025){ref-type="ref"}). Variant calling was performed according to GATK Best Practice recommendations using GATK version 3.1 (McKenna et al., [2010](#mgg3850-bib-0030){ref-type="ref"}) including local realignment around insertion/deletions (indels) and recalibration of quality scores. The variant caller HaplotypeCaller was utilized. Quality control of the called variants was performed using GATK variant filtration with parameter settings according to the recommendations in SEQanswers exome sequencing analysis guide (Van der Auwera et al., [2013](#mgg3850-bib-0040){ref-type="ref"}). In short, variant quality score recalibration (VQSR) was applied using the recommended set of known variants for both indels and SNP. The tranche threshold of 99.0 was used to select variants. ANNOVAR (Wang, Li, & Hakonarson, [2010](#mgg3850-bib-0044){ref-type="ref"}) was used to annotate detected variants and filtering of variants was done using the filtering tool FILTUS version 1.0.4 (Vigeland, Gjotterud, & Selmer, [2016](#mgg3850-bib-0043){ref-type="ref"}).

2.5. Filtering of variants {#mgg3850-sec-0011}
--------------------------

FILTUS, a desktop software for fast and efficient detection of disease‐causing variants was used on the annotated files (Vigeland et al., [2016](#mgg3850-bib-0043){ref-type="ref"}). The 10 MMR genes belonging to the gene panel previously analyzed by Hansen et al. ([2017](#mgg3850-bib-0014){ref-type="ref"} were also included in the current study due to different filtering strategies and for comparative purposes.

Variants were filtered in the 22 MMR genes individually (gene lookup in FILTUS), with function collapse = lists all samples that have same variant together and saved as individual files on gene name, before being combined into one file. Variants with a frequency of more than 0.05 in public databases (ExaC or gNomad (Lek et al., [2016](#mgg3850-bib-0023){ref-type="ref"})) were first excluded. Then variants were excluded if detected in more than five unrelated individuals in our cohort (not likely to be pathogenic due to their high frequency) and intronic variants were ignored if they had no variant prediction. Nonsynonymous single‐nucleotide variants (SNVs) and indel variants were included in further filtering.

After in silico filtering, using FILTUS, we performed some manual filtering and variant interpretation to remove artifacts and only selecting variants most likely to be causative. We checked detected variants against results reported by Hansen et al. ([2017](#mgg3850-bib-0014){ref-type="ref"}. Further, variant interpretation was performed utilizing Alamut software (Interactive Biosoftware, Rouen, France) and evaluating available literature.

After the initial filtering step of each gene individually using FILTUS, we identified 29 potential pathogenic exonic indels and 170 exonic nonsynonymous SNVs. We applied the following nonsynonymous variant categorical predictions: AVSIFT score \<0.05 = deleterious, LJB PhyloP prediction = conserved (\>0.95), LJB SIFT = damaging (\>0.99), LJB PolyPhen2 = damaging (\>0.85), LJB LRT = deleterious (\>0.99), MutationTaster = damaging (\>0.59), GERP++ (\>3.0 -- except one with a score of 1.84) which resulted in 50 exonic nonsynonymous SNVs being identified that were predicted to be deleterious/damaging by in silico analysis. All of the variants identified in this study were heterozygous. After additional manual filtering, 25 possible causative variants remained in our list (see Table [2](#mgg3850-tbl-0002){ref-type="table"}).

###### 

List of variants identified in LS screened MMR genes (*MLH1*, *MSH2*, and *MSH6*) and other MMR genes (*EXO1*, *POLD1*, *RFC1*, and *RPA1*)

  Gene    Hansen et al. (Hansen et al., [2017](#mgg3850-bib-0014){ref-type="ref"})   Reference sequence   DNA change                AA change           Domain                                                          Rs ID[a](#mgg3850-note-0007){ref-type="fn"}   gnomad AF[a](#mgg3850-note-0007){ref-type="fn"}   Classification      Type         Sample ID
  ------- -------------------------------------------------------------------------- -------------------- ------------------------- ------------------- --------------------------------------------------------------- --------------------------------------------- ------------------------------------------------- ------------------- ------------ -------------
  MLH1    [b](#mgg3850-note-0008){ref-type="fn"}                                     NM_000249.3          c.514G \> A               p.Glu172Lys                                                                         NR                                            NR                                                VUS                 Missense     250
  MLH1                                                                               NM_001167619.2       c.1130A \> C              Lys377Thr                                                                           rs63750449                                    0.004564                                          VUS                 Missense     187 and 214
  MLH1    [b](#mgg3850-note-0008){ref-type="fn"}                                     NM_000249.3          c.2103 + 1G\>T            N/A                                                                                 rs267607888                                   N/A                                               Pathogenic          Missense     116
  MLH1                                                                               NM_000249.3          c.1039−31_1039−29delATA   N/A                                                                                 rs778381149                                   0.0003969                                         VUS                 Intronic     295
  MSH2    [b](#mgg3850-note-0008){ref-type="fn"}                                     NM_000251.2          c.138C \> G               p.His46Gln                                                                          rs33946261                                    0.0003619                                         Likely Pathogenic   Missense     9
  MSH2    [b](#mgg3850-note-0008){ref-type="fn"}                                     NM_000251.2          c.1045C \> G              p.Pro349Ala                                                                         rs267607939                                   0.00009148                                        Likely Pathogenic   Missense     281
  MSH6                                                                               NM_000179.2          c.431G \> T               p.Ser144Ile         DNA binding PWWP domain                                         rs3211299                                     0.001187                                          Benign              Missense     201
  MSH6                                                                               NM_001281492.1       c.892A \> G               p.Lys298Glu                                                                         rs761822293                                   0.000003979                                       VUS                 Missense     169
  MSH6                                                                               NM_001281492.1       c.1054C \> T              p.Arg352X                                                                           rs63750909                                    0.00003186                                        Pathogenic          Nonsense     133
  MSH6                                                                               NM_001281492.1       c.1118C \> G              p.Ser373Cys                                                                         rs63750897                                    0.001165                                          Likely Benign       Missense     225
  MSH6    [b](#mgg3850-note-0008){ref-type="fn"}                                     NM_000179.2          c.1282A \> G              p.Lys428Glu                                                                         rs761822293                                   0.000003979                                       VUS                 Missense     169
  MSH6    [b](#mgg3850-note-0008){ref-type="fn"}                                     NM_000179.2          c.2079dup                 p.Cys694Metfs\*4                                                                    rs267608083                                   NR                                                Pathogenic          Frameshift   183
  MSH6    [b](#mgg3850-note-0008){ref-type="fn"}                                     NM_000179.2          c.3261 dup                p.Phe1088Leufs\*5                                                                   rs748452299                                   0.0018                                            Pathogenic          Frameshift   41
  EXO1                                                                               NM_003686.4          c.1928T \> A              p.Leu643X           MLH1 and MSH2 interaction domain removed                        NR                                            N/A                                               VUS                 Nonsense     165
  EXO1                                                                               NM_003686.4          c.2009A \> G              p.Glu670Gly         MSH2 interaction domain                                         rs1776148                                     0.78                                              Benign              Missense     166
  EXO1                                                                               NM_006027 0.4        c.2485G \> T              p.Glu829X           MLH1 interaction domain removed                                 rs757677420                                   0.00000292                                        VUS                 Nonsense     154
  POLD1                                                                              NM_001256849.1       c.1249A \> G              p.Thr417Ala         DNA‐directed DNA polymerase, family B exonuclease domain        NR                                            N/A                                               VUS                 Missense     226
  POLD1                                                                              NM_001256849.1       c.1558insG                p\.                 DNA‐directed DNA polymerase, family B, multifunctional domain   NR                                            N/A                                               VUS                 Frameshift   109
  POLD1                                                                              NM_001256849.1       c. 2510G \> C             p.Gly811Ala         DNA‐directed DNA polymerase, family B multifunctional domain    NR                                            N/A                                               VUS                 Missense     277
  RFC1                                                                               NM_001204747.1       c.2017G \> A              p.Val673Met         ATPase domain                                                   rs28903096                                    0.0006994                                         VUS                 Missense     174
  RFC1                                                                               NM_001204747.1       c.2276A \> G              p.Lys759Arg         ATPase domain                                                   NR                                            N/A                                               VUS                 Missense     227
  RPA1                                                                               NM_002945.4          c.856G \> T               p.Val286Phe                                                                         rs55800538                                    0.002942                                          VUS                 Missense     161
  RPA1                                                                               NM_002945.4          c.1160G \> A              p.Gly387Asp         OB domain                                                       NR                                            N/A                                               VUS                 Missense     239
  RPA1                                                                               NM_002945.4          c.1165C \> T              p.Arg389W           OB domain                                                       rs202068855                                   0.0005468                                         VUS                 Missense     221
  MLH3    [b](#mgg3850-note-0008){ref-type="fn"}                                     NM_001040108.1       c.885del                  p.His296Thrfs\*12                                                                   NR                                            N/A                                               VUS                 Frameshift   14

Reported here are the gene symbol, Refseq reference sequence, DNA and amino acid (AA) change, protein domain, the rs ID of the variant if known, then gnomad allele frequency and the classification according to the ACMG 2015 guidelines (Richards et al., [2015](#mgg3850-bib-0034){ref-type="ref"}).

Not reported (NR) ‐ previously unreported variant.

Variant previously identified in Hansen et al. ([2017](#mgg3850-bib-0014){ref-type="ref"}).

John Wiley & Sons, Ltd

2.6. Validation of detected variants and segregation analysis by Sanger sequencing {#mgg3850-sec-0012}
----------------------------------------------------------------------------------

Sanger sequencing was used to confirm possible pathogenic variants remaining after applying filtering steps described above. The fragments were amplified using AmpliTaq Gold® 360 MasterMix and 360 GC Enhancer (Life Technologies). Cycle sequencing reaction was performed with BigDye® Terminator v3.1 (Life Technologies) and subsequent capillary electrophoresis was performed on the ABI 3130xl or ABI 3730 (Life Technologies). Sanger sequencing data were analyzed using SeqScape Software v3.0 (Life Technologies).

3. RESULTS {#mgg3850-sec-0013}
==========

After the final filtering, 25 possible causative variants remained (see Table [2](#mgg3850-tbl-0002){ref-type="table"}). Of these 25 variants, six were predicted to be pathogenic (24%), all located in either *MLH1* or *MSH6*.

3.1. Variants identified in MMR genes already linked to LS {#mgg3850-sec-0014}
----------------------------------------------------------

We identified 13 variants in *MLH1*, *MSH2*, and *MSH6*, seven previously reported by Hansen et al. ([2017](#mgg3850-bib-0014){ref-type="ref"} will not be discussed further. Two nonsynonymous variants were identified in *MLH1*; c.1130A \> C and an intronic ATA deletion (rs778381149) upstream of exon 12 in a highly variable region of DNA. Two unrelated individuals were identified with the c.1130A \> C variant.

In *MSH6*, four separate variants were found (each in different individuals); c.1054C \> T, c.431G \> T, c.1118C \> G, and c.892A \> G. The c.1054C \> T variant is a nonsense variant resulting in a truncated protein p.R352X previously described as pathogenic (ClinVar variation ID: 89194). The c.431G \> T and c.1118C \> G variants are classified as benign and likely benign respectively, while c.892A \> G is of unknown significance.

Of the 13 variants in *MLH1*, *MSH2*, and *MSH6*, four are considered pathogenic or likely pathogenic; two of the samples had not been tested for the gene where we found the variant previously (one due to IHC results indicating MLH1/PMS2 when the variant found is in MSH2). The other two were tested in late 1990s or early 2000.

3.2. Variants identified in the other 18 MMR genes {#mgg3850-sec-0015}
--------------------------------------------------

Five additional MMR genes were found to harbor 12 variants in our cohort (see Table [2](#mgg3850-tbl-0002){ref-type="table"}). A frameshift variant in *MLH3* will not be discussed further as it has been previously described (Hansen et al., [2017](#mgg3850-bib-0014){ref-type="ref"}). *EXO1*, *POLD1*, *RFC1*, and *RPA1* were all found to harbor variants, one benign and the remaining variants of unknown significance (VUSs). Moreover, the variants (except *RFC1* c.2276A \> G and POLD1 c.2510G \> C) were nonconservative, suggesting the resultant amino acid is significantly different from the original.

*EXO1* harbored three different variants; c.2009A \> G is a missense variant leading to a change of amino acid from glutamic acid to glycine, p.(Glu670Gly), the variant affects the interaction domain between MSH2 and EXO1 but is predicted to be benign. Two nonsense variants were also identified in two different patients; c.1928T \> A and c.2485G \> T both predicted to result in a truncated protein p.L643X and p.E829X. The p.L643X variant misses both MLH1 and MSH2 interaction domains and the p.E829X misses only the MLH1 interaction domain. Failing to recruit the EXO1 protein with the recognition complex would lead to a defective MMR pathway, the accumulation of pathogenic variant and MSI.

*POLD1* encodes for the catalytic subunit of the polymerase delta. Three different VUSs were detected in this gene. The c.1558insG is a frameshift variant that would most likely affect POLD1 mRNA, leading to RNA degradation and no protein expression. Two other missense variants were identified; c.1592A \> G and c2510G \> C both located between protein domains.

*RFC1* codes for the subunit 1 of the Replication Factor C. Two different variants were identified; c.2017G \> A and c.2276A \> G. The two variants of *RFC1* are both located on the ATPase functional domain of the protein subunit. RFC acts as a clamp loader for PCNA during DNA replication and damage repair. DNA resynthesis is significantly impaired by the loss of function of both RFC1 and PCNA.

Three variants were found in *RPA1*, namely c.856G \> T, c.1165C \> T and c.1160G \> A. Two of these, c.1165C \> T and c.1160G \> A, were located in the oligonucleotide/oligosaccharide‐binding domain (OB) domain. The OB domain allows RPA1 protein to bind ssDNA in a nonsequence‐specific manner and to stabilize the single strand after the damaged strand is excised (Bochkareva, Korolev, Lees‐Miller, & Bochkarev, [2002](#mgg3850-bib-0002){ref-type="ref"}). The remaining variant c.856G \> T did not appear to alter the functional domain of the protein.

4. DISCUSSION {#mgg3850-sec-0016}
=============

The presence of potentially pathogenic variants in patients diagnosed with LLS shows that there is a clear need to create an exhaustive list of pathogenic or potentially pathogenic genes for inherited CRC in order to identify individuals with a high risk of developing CRC and genes/variants appropriate for functional analysis. MMR genes are good candidates given that they are predicted to be causative in 8% of patients in the current study, a yield comparable to similar studies (Dong et al., [2018](#mgg3850-bib-0008){ref-type="ref"}; Paulo et al., [2018](#mgg3850-bib-0033){ref-type="ref"}). In addition, our results suggest that re‐screening the four known LS genes in previously variant‐negative LS patients with the more sensitive approach of NGS should be undertaken to ensure no pathogenic variants have been missed using less sensitive screening methods.

From the 274 patients enrolled in this study and not previously described we revealed 22 potentially causative variants in nine different MMR genes. Included in the study were the four known LS MMR genes (*MSH2*, *MLH1*, *MSH6*, and *PMS2*) as it is well accepted that older variant detection methods were not as sensitive as approaches that are more contemporary. The number of variants identified in *MLH1* and *MSH6* reflects the sensitivity of older screening methodologies that may not have revealed the presence of these causative variants. We detected additional variants in *MLH1* and *MSH6* compared to Hansen et al. ([2017](#mgg3850-bib-0014){ref-type="ref"} due to less stringent filtering strategies in FILTUS.

The identification of 11 potentially pathogenic variants through in silico analysis in the extended MMR gene panel does reveal the extent to which the DNA MMR pathway might be associated with the risk of cancer development in families classified as LLS. We show here that families categorized as LLS harbor potentially pathogenic variants in other MMR genes than those already associated with LS. The genes *EXO1*, *POLD1*, *RFC1*, and *RPA1* harbor that variants that were predicted to be pathogenic. None of the variants identified in this study have previously been associated with a cancer phenotype, which is probably due to their extremely low frequency in the general population. However, disrupting the MMR pathway could be a possible cause of cancer development. It is known that *RFC1*, *RPA1*, and *POLD1* are involved in DNA damage repair mechanisms other than MMR and DNA synthesis during replication (see KEGG orthology: K10754, K02999 and K02327). *EXO1* is involved with other DNA repair and maintenance mechanisms (Keijzers, Liu, & Rasmussen, [2016](#mgg3850-bib-0021){ref-type="ref"}). Interestingly, the two nonsense *EXO1* variants identified in our study are predicted to affect the binding to *MSH2*/*MLH1*, suggesting that the loss of function would specifically affect *EXO1* MMR‐related functions. Moreover, *RPA1* and *POLD1* have been previously described as deleterious when mutated in cancer (Nicolas, Golemis, & Arora, [2016](#mgg3850-bib-0031){ref-type="ref"}; Wang et al., [2005](#mgg3850-bib-0046){ref-type="ref"}). Variants in *POLD1* are described in patients presenting a polyposis phenotype termed polymerase‐proofreading associated polyposis (PPAP) (Palles et al., [2013](#mgg3850-bib-0032){ref-type="ref"}). The pathogenic variants identified in *POLD1* in the current study support the notion that the phenotypes of LS and PPAP might overlap, both with a multitumor phenotype.

*RPA1* variants have previously been implicated in cancers that are associated with chromosome instability (Hass, Gakhar, & Wold, [2010](#mgg3850-bib-0015){ref-type="ref"}; Wang et al., [2005](#mgg3850-bib-0046){ref-type="ref"}). However, a comprehensive genetic study did not show a clear association with CRC (Jokic et al., [2011](#mgg3850-bib-0019){ref-type="ref"}).

A meta‐analysis supports a significant association between RFC1 p.G80A and plasma cell malignancies (Huang et al., [2016](#mgg3850-bib-0017){ref-type="ref"}). Moreover, the Cancer Genome Atlas (TCGA data) (Cancer Genome Atlas Research et al., [2013](#mgg3850-bib-0048){ref-type="ref"}) shows that somatic *RFC1* variants occur in 10.2% of uterine cancers and 5.5% of CRCs, which is consistent with tumors identified in LS. RFC1 has been previously described as a member of the BRCA1‐associated genome surveillance complex (BASC) (Wang et al., [2000](#mgg3850-bib-0045){ref-type="ref"}). This complex is involved in DNA damage and abnormal structure detection and more generally in the maintenance of genomic integrity making it a good candidate gene for LLS.

Pathogenic variants in *EXO1* were also found in the current study but its exact role remains to be determined. A previous study suggests that the gene is either associated with low‐disease penetrance or influencing a polygenic risk score (Talseth‐Palmer et al., [2016](#mgg3850-bib-0038){ref-type="ref"}). Other reports indicate that even in healthy patients, *EXO1* variants are present, including those that result in a truncated protein (Jagmohan‐Changur et al., [2003](#mgg3850-bib-0018){ref-type="ref"}) and consequently loss of function. Notwithstanding, in our study, both *EXO1* c.1928T \> A and c.2485G \> T leads to a truncated protein. The variant c.1928T \> A has lost the MLH2 and MLH1 interaction domain, whereas the c.2485G \> T variant truncates only the MLH1 interaction domain. Lack of either of these domains could affect EXO1 recruitment at the site of the mismatch or DNA damage, impairing the MMR process (Goellner, Putnam, & Kolodner, [2015](#mgg3850-bib-0012){ref-type="ref"}).

To assess the link between the variants identified in the current study and the development of CRC in LLS families, larger sample cohorts are needed with detailed analysis of the tumor phenotypes to establish if indeed many of the downstream MMR functions are associated with MSI tumors. Furthermore, detailed segregation analysis is required to determine if the variant segregates with disease. Finally, functional analysis would significantly aid in characterizing their respective pathogenic effects.

Limitations of the current study include the relatively small number of patients tested. A larger sample cohort and functional studies of the identified variants are required to confirm the results of this study. Segregation analysis would provide insights into the pathogenicity of these variants but could not be performed as part of this study.

In conclusion, we have shown that other genes associated with the process of DNA MMR have a high probability of being associated with LLS families. In addition, approximately 8% of families that fulfill the ACII or RB criteria in our sample cohort appear to be accounted for by genes involved in the MMR pathway. These findings indicate that these variants are important as they will guide future research focused on the functional impact of newly discovered variants.

![Mismatch repair pathway major steps with genes associated. Genes in red are the one usually screened for mutations in a clinical setting. *MLH1*, *PMS2*, *MSH2*, and *MSH6* are all involved in the recognition of DNA damage. PMS2 has an endonuclease function in nicking around the damaged region. EXO1 will then remove the DNA strand containing the error and RPA (Replication Protein A) will protect the remaining single strand of DNA. The DNA polymerase Polδ resynthesises the new DNA strand which is then ligated with a ligase (based on Hsieh & Yamane, [2008](#mgg3850-bib-0016){ref-type="ref"})](MGG3-7-e850-g001){#mgg3850-fig-0001}
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